Skip to content
Yog Pharma
Central nervous systemGabapentinoid anticonvulsant

Gabapentin is a gabapentinoid anticonvulsant indicated for postherpetic neuralgia and adjunctive therapy for partial-onset seizures. We supply it to US manufacturers of capsules, tablets and oral solution.

CAS60142-96-3171.2 g/molC9H17NO2
2D structure of Gabapentin.

Data from PubChem (CID 3446) and FDA’s substance registry

CAS number

60142-96-3

Molecular formula

C9H17NO2

Molecular weight

171.2g/mol

FDA UNII

IUPAC name

2-[1-(aminomethyl)cyclohexyl]acetic acid

InChIKey

UGJMXCAKCUNAIE-UHFFFAOYSA-N

Appearance
White to off-white crystalline solid.
Solubility
Freely soluble in water and in both basic and acidic aqueous solutions.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Gabapentin cyclizes to a lactam on storage, and the lactam limit is tight. Ask for stability data and the lactam result on recent batches.

On the US market

Reference product
NeurontinNDA 020235
Approved ANDAs
44 with a marketed product
Approved forms and strengths
  • Capsule 100 mg, 200 mg, 300 mg, 400 mg
  • Tablet 100 mg to 900 mg, in 8 strengths
  • Oral solution 250 mg/5 mL

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com